We’re committed to advancing cardiology through less invasive technologies that improve outcomes, deliver care to more patients, reduce costs, and help millions live healthier lives.
Delivering Meaningful Innovation
A Pioneering Alternative to Blood Thinners. The WATCHMAN™ Left Atrial Appendage Closure Device is the only FDA-approved alternative to blood thinners for reducing atrial fibrillation stroke risk. Now covered by Medicare and Medicaid, the launch of WATCHMAN further solidified our position in the structural heart market.
Healing with Confidence. The SYNERGY™ System is the only FDA-approved stent with bioabsorbable polymer coating, which promotes healing and frees patients from long-term polymer exposure. The launch of SYNERGY continues to improve patients’ lives while boosting Interventional Cardiology performance.
First of its Kind. The Lotus™ Valve System* is the first device of its kind that is both fully repositionable and retrievable prior to release. Positive results in clinical studies reinforce the safety and efficacy of this less invasive treatment option for patients with severe aortic valve stenosis who are at high risk for surgical valve replacement.
*Lotus is an investigational device and not available for sale in the U.S.
Conditions We Treat
Solutions We Offer
1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2014 update. A report from the American Heart Association. Circulation 2014; 129: e28-e292.
2. Colilla et al. Am J Cardiology, 2013; 112:1142-1147.
3. Holmes, DR et al. Seminars in Neurology, 2010; 30:528–536.